The Food and Drug Administration said Tuesday that data from Pfizer’s coronavirus vaccine trials was consistent with recommendations put forth by the agency for an emergency use authorization. It also said the vaccine was highly effective and did not raise any specific safety concerns.
In documents published ahead of an advisory meeting Thursday to review Pfizer’s vaccine, FDA staff also said data submitted appeared to show the vaccine was at least 52% effective before the second dose and 82% effective for the combined group of people who took one or two doses.
Pfizer’s vaccine recommends two doses about three weeks apart. The agency added that two doses of the vaccine were “highly effective” in preventing confirmed cases of Covid-19 at least seven days following the second dose. Read more…
